Recent Security Class Actions

Immunovant Inc. Common Stock (NASDAQ: IMVT)

Company Name:Immunovant Inc. Common Stock
Stock Symbol:NASDAQ: IMVT
Class Period Start:10/02/2019
Class Period End (inclusive):02/01/2021
Filing Deadline:04/20/2021

According to the Complaint, Immunovant, Inc. is a clinical-stage biopharmaceutical company that develops monoclonal antibodies for the treatment of autoimmune diseases. On September 29, 2019, Health Sciences Acquisitions Corporation (“HSAC”), then a blank check company, or SPAC, entered into an agreement with Legacy Immunovant, a private biopharmaceutical company, and shareholders of Legacy Immunovant, to effect a merger between the two entities. As a result of the Merger, HSAC acquired all of the issued and outstanding shares of Legacy Immunovant, and Legacy Immunovant became a wholly owned subsidiary of HSAC. Upon the closing of the Merger, HSAC changed its name to “Immunovant, Inc.”